Table 2.
Tumour characteristics
|
All patients (n = 102) %(n) |
Under 50yr (n = 26) %(n) |
50yrs or over (n = 76) %(n) |
|
|---|---|---|---|
| Stage | |||
| ◦ 1 | 28 (28) | 31 (8) | 26 (20) |
| ◦ 2 | 51 (52) | 50 (13) | 51 (39) |
| ◦ 3 | 22 (22) | 19 (5) | 22 (17) |
| Tumour size | |||
| ◦ <=2 cm | 39 (40) | 46 (12) | 37 (28) |
| ◦ > 2-5 cm | 43 (44) | 39 (10) | 45 (34) |
| ◦ > 5 cm | 18 (18) | 15 (4) | 18 (14) |
| No of positive nodes | |||
| ◦ 0 | 47 (48) | 46 (12) | 47 (36) |
| ◦ 1–3 | 33 (34) | 39 (10) | 32 (24) |
| ◦ 4–9 | 14 (14) | 12 (3) | 15 (11) |
| ◦ 10 or more | 6 (6) | 4 (1) | 7 (5) |
| Grade | |||
| ◦ 1 | 1 (1) | 0 (0) | 1 (1) |
| ◦ 2 | 34 (35) | 19 (5) | 40 (30) |
| ◦ 3 | 65 (66) | 81 (21) | 59 (45) |
| Receptor status | |||
| ◦ ER+/HER2- | 60 (61) | 65 (17) | 58 (44) |
| ◦ ER+/HER2+ | 29 (30) | 23 (6) | 32 (24) |
| ◦ ER-/HER2+ | 6 (6) | 4 (1) | 7 (5) |
| ◦ Triple negative | 5 (5) | 8 (2) | 4 (3) |